# US 2024/0003908 A1 · Polyol biomarkers for congenital disorders of glycosylation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003908 A1
- Document ID: US20240003908A1
- Status: Published application
- Kind: A1
- Application number: 18/036,031
- Filed: 2021-11-10
- Published: 2024-01-04
- Earliest claimed: 2020-11-10
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Eva Morava-Kozicz; Tamas Kozicz; Devin Oglesbee; Kimiyo M. Raymond
- Web page: https://patentgrep.com/patent/US20240003908A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/426: 1,3-Thiazoles
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- C12N 9/90: Isomerases (5.)
- C12Y 504/02008: Phosphomannomutase (5.4.2.8)
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 2440/38: addition of carbohydrates, e.g. glycosylation, glycation
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Methods and materials for assessing the severity of congenital disorders of glycosylation (CDG), as well as methods and materials for treating CDG patients based on the assessment of CDG severity.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

A method for treating a mammal identified as (a) having a CDG and (b) having a biological sample containing an elevated level of one or more polyols, relative to the level of said one or more polyols in a biological sample from a control mammal not having said CDG,
wherein said method comprises administering to said mammal a dose of an aldose reductase inhibitor (ARI) that is increased as compared to a dose of said ARI that would be administered to a mammal identified as having said CDG and as having a biological sample that does not contain an elevated level of said one or more polyols, relative to the level of said one or more polyols in said biological sample from said control mammal.

### Claim 10 (depends on 9)

The method of claim 9, wherein said mammal to which said increased dose of ARI is administered is a human.

### Claim 11 (depends on 9)

The method of claim 9, wherein said CDG is a Type II CDG.

### Claim 12 (depends on 9)

The method of claim 9, wherein said CDG is PMM2-CDG.

### Claim 13 (depends on 9)

The method of claim 9, wherein said one or more polyols comprise one or more of mannitol, sorbitol, maltitol, xylitol, and erythritol.

### Claim 14

(canceled)

### Claim 15 (depends on 9)

The method of claim 9, wherein said biological sample is a urine sample or a blood sample.

### Claim 16 (depends on 9)

The method of claim 9, wherein said ARI comprises epalrestat, AT007, alrestatin, benurestat, epalrestat, fidarestat, imirestat, lidorestat, minalrestat, ponalrestat, ranirestat, risarestat, sorbinil, tolrestat, zenarestat, or zopolrestat.

### Claim 17 (depends on 9)

The method of claim 9, wherein the elevated level of said one or more polyols is increased by at least 10% as compared to the level of said one or more polyols in the biological sample from said control mammal.

### Claim 18 (depends on 9)

The method of claim 9, wherein said increased dose is from about 0.5 mg/kg/day to about 5 mg/kg/day.

### Claim 19 (depends on 9)

The method of claim 9, wherein said increased dose is at least about 50% greater than a dose of the ARI previously administered to said mammal.

### Claim 20

A method for treating a mammal identified as having a CDG, the method comprising:
(a) measuring a level of one or more polyols in a biological sample from said mammal, and determining that a measured level of at least one of said one or more polyols is elevated relative to a level of the one or more polyols in a biological sample from a control mammal that does not have said CDG, and
(b) administering to said mammal a dose of an ARI that is increased as compared to a dose of said ARI that would be administered to a mammal identified as having said CDG and as having a biological sample that does not contain an elevated level of said one or more polyols, relative to the level of said one or more polyols in said biological sample from said control mammal.

### Claim 21 (depends on 20)

The method of claim 20, wherein said mammal to which said increased dose of ARI is administered is a human.

### Claim 22 (depends on 20)

The method of claim 20, wherein said CDG is a Type II CDG.

### Claim 23 (depends on 20)

The method of claim 20, wherein said CDG is PMM2-CDG.

### Claim 24 (depends on 20)

The method of claim 20, wherein said one or more polyols comprise one or more of mannitol, sorbitol, maltitol, xylitol, and erythritol.

### Claim 25

(canceled)

### Claim 26 (depends on 20)

The method of claim 20, wherein said biological sample is a urine sample or a blood sample.

### Claim 27 (depends on 20)

The method of claim 20, wherein said ARI comprises epalrestat AT007, alrestatin, benurestat, epalrestat, fidarestat, imirestat, lidorestat, minalrestat, ponalrestat, ranirestat, risarestat, sorbinil, tolrestat, zenarestat, or zopolrestat.

### Claim 28 (depends on 20)

The method of claim 20, wherein the elevated level of said one or more polyols is increased by at least 10% as compared to the level of said one or more polyols in the biological sample from said control mammal.

### Claim 29 (depends on 20)

The method of claim 20, wherein said increased dose is from about 0.5 mg/kg/day to about 5 mg/kg/day.

### Claim 30 (depends on 20)

The method of claim 20, wherein said increased dose is at least about 50% greater than a dose of the ARI previously administered to said mammal.
